Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22014999 | 0.87 | — | — | |
| SCHEMBL22014721 | 0.85 | — | — | |
| SCHEMBL21962221 | 0.82 | KDM4E (0.32) | — | |
| SCHEMBL29687381 | 0.82 | KDM4E (0.32) | — | |
| SCHEMBL23319827 | 0.81 | — | — | |
| SCHEMBL22015607 | 0.81 | HSP90AA1 (0.33) | — | |
| SCHEMBL22014398 | 0.79 | — | — | |
| SCHEMBL22015606 | 0.78 | — | — | |
| SCHEMBL21962082 | 0.77 | KDM4E (0.33) | PLA2G10PLA2G5 | |
| SCHEMBL19507330 | 0.74 | MTNR1A (0.40) | MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2020102100-A9 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-01-06 | — | — | WO | disclosed |
| US-20210395241-A1 | NLRP MODULATORS | NOVARTIS INFLAMMASOME RESEARCH, INC. | 2021-12-23 | — | — | US | disclosed |
| CN-113613721-A | NLRP modulators | 诺华股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3880666-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166081-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3817815-A1 | NLRP MODULATORS | Novartis AG (CH) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020102100-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395241-A1 | NLRP MODULATORS | NLRP1, NLRP3, NOD1 | PLA2G10 1505/4885PLA2G5 3048/4885MTNR1A 1176/4885 |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | PLA2G10 833/4885PLA2G5 2294/4885MTNR1A 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.